1887

Chapter 2 : Entry Inhibitors of Human Immunodeficiency Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Entry Inhibitors of Human Immunodeficiency Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap02-1.gif /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap02-2.gif

Abstract:

Highly active antiretroviral therapy (HAART) based on the combination of different classes of inhibitors has dramatically improved the prognosis of human immunodeficiency virus type 1 (HIV-1) infection after its establishment. This chapter focuses on the viral entry processes that play crucial roles in HIV-1 replication and describes inhibitors thereof. It talks about three kinds of inhibitor named as fusion inhibitors, coreceptor inhibitors and viral attachment inhibitors. Maraviroc was approved for use in combination with other antiretroviral medications for the treatment of R5 HIV-1 in adults whose viral loads remain detectable despite existing antiretroviral treatment or who have multidrug-resistant HIV-1. HIV-1 variants resistant to Cyanovirin-N (CV-N) or cross-resistant to additional carbohydrate-binding agents were generated and examined for their biological properties. A study on resistance to CV-N demonstrated that the resistant variants had increased susceptibility to immunoglobulins and sera obtained from HIV-1-infected patients and particularly to V3-loop-directed monoclonal antibodies. The maraviroc-resistant R5 HIV-1 retained full susceptibility to SCH-C and aplaviroc, suggesting that although the CCR5 binding sites for these agents are similar, their impacts on the surface conformation of the receptor are different. The results of the study also suggest that the envelope proteins of maraviroc-resistant viruses are able to recognize and utilize inhibitor-bound CCR5, which involves the ordered accumulation of mutations in the viral envelope, both in the V3 loop and elsewhere within gp120. In addition to the inhibitors described in the chapter, several antibodies have been shown to interact with the molecules essential for HIV-1 entry to the host cells.

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2

Key Concept Ranking

Viral Entry Via Membrane Fusion
0.46158367
0.46158367
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1.
Figure 1.

A schematic presentation of HIV-1 entry. (a) The first step of HIV-1 entry to the host cells is gp120 binding to the primary receptor CD4. (b) After binding, the conformation of gp120 changes, which induces exposure of the coreceptor binding domain. Consequently, gp120 binds to a coreceptor, either CCR5 or CXCR4. (c) The binding of gp120 to a coreceptor leads to conformational changes of gp41 that allow insertion of its fusion peptide into the target cell membrane. (d) Then, the heptad repeat (HR-1 and HR-2) regions of gp41 fold into a six-helix bundle (hairpin structure). (e) The bundle formation brings viral envelope and cell membrane closer together and facilitates their fusion. The closed arrows indicate the molecules or steps that entry inhibitors interact with.

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Chemical structures of viral attachment inhibitors. (a) BMS-378806; (b) BMS-488043.

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Chemical structures of CXCR4 inhibitors. (a) AMD3100; (b) KRH-1636.

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4.
Figure 4.

Chemical structures of CCR5 inhibitors. (a) TAK-779; (b) SCH-C (SCH 351125); (c) maraviroc (UK-427,857); (d) vicriviroc (SCH-D); (e) aplaviroc (GW873140/ONO4128); (f) TAK-220; (g) TAK-652; (h) CMPD167; (i) AMD3451.

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5.
Figure 5.

A schematic presentation of gp41 and enfuvirtide structure. gp41 consists of the fusion peptide (FP), two regions of the hydrophobic heptad repeat (HR-1 and HR-2), the transmembrane segment (TM), and the cytoplasmic region (not drawn in this schema). Enfuvirtide is a synthetic 36-amino-acid peptide corresponding to residues 643 to 678 in HR-2.

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815493.ch02
1. Adkison, K. K.,, A. Shachoy-Clark,, L. Fang,, Y. Lou,, K. O’Mara,, M. M. Berrey, and, S. C. Piscitelli. 2005. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob. Agents Chemother. 49:28022806.
2. Arakaki, R.,, H. Tamamura,, M. Premanathan,, K. Kanbara,, S. Ramanan,, K. Mochizuki,, M. Baba,, N. Fujii, and, H. Nakashima. 1999. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol. 73:17191723.
3. Baba, M., and, E. De Clercq. 1990. Sulfated polymers as inhibitors of HIV replication, p. 85–101. In E. De Clercq (ed.), Design of Anti-AIDS Drugs, Elsevier, Amsterdam, The Netherlands.
4. Baba, M.,, H. Miyake,, X. Wang,, M. Okamoto, and, K. Takashima. 2007. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 51:707715.
5. Baba, M.,, O. Nishimura,, N. Kanzaki,, M. Okamoto,, H. Sawada,, Y. Iizawa,, M. Shiraishi,, Y. Aramaki,, K. Okonogi,, Y. Ogawa,, K. Meguro, and, M. Fujino. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96:56985703.
6. Baba, M.,, K. Takashima,, H. Miyake,, N. Kanzaki,, K. Teshima,, X. Wang,, M. Shiraishi, and, Y. Iizawa. 2005. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 49:45844591.
7. Baba, M.,, R. Pauwels,, J. Balzarini,, J. Arnout,, J. Desmyter, and, E. De Clercq. 1988. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85:61326136.
8. Balzarini, J. 2007. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 5:583597.
9. Balzarini, J.,, K. Van Laethem,, W. J. Peumans,, E. J. Van Damme,, A. Bolmstedt,, F. Gago, and, D. Schols. 2006. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. Virol. 80:84118421.
10. Berger, E. A.,, P. M. Murphy, and, J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657700.
11. Bolmstedt, A. J.,, B. R. O’Keefe,, S. R. Shenoy,, J. B. McMahon, and, M. R. Boyd. 2001. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol. Pharmacol. 59:949954.
12. Boyd, M. R.,, K. R. Gustafson,, J. B. McMahon,, R. H. Shoemaker,, B. R. O’Keefe,, T. Mori,, R. J. Gulakowski,, L. Wu,, M. I. Rivera,, C. M. Laurencot,, M. J. Currens,, J. H. Cardellina II,, R. W. Buckheit, Jr.,, P. L. Nara,, L. K. Pannell,, R. C. Sowder II, and, L. E. Henderson. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glyco-protein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41:15211530.
13. Chan, D. C., and, P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681684.
14. Connor, R. I.,, K. E. Sheridan,, D. Ceradini,, S. Choe, and, N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621628.
15. Daelemans, D.,, D. Schols,, M. Witvrouw,, C. Pannecouque,, S. Hatse,, S. van Dooren,, F. Hamy,, T. Klimkait,, E. De Clercq, and, A. M. Vandamme. 2000. A second target for the peptoid Tat/ transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXCchemokine receptor 4-mediated virus entry. Mol. Pharmacol. 57:116124.
16. Dean, M.,, M. Carrington,, C. Winkler,, G. A. Huttley,, M. W. Smith,, R. Allikmets,, J. J. Goedert,, S. P. Buchbinder,, E. Vittinghoff,, E. Gomperts,, S. Donfield,, D. Vlahov,, R. Kaslow,, A. Saah,, C. Rinaldo,, R. Detels, and, S. J. O’Brien. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:18561862.
17. De Clercq, E. 2002. New anti-HIV agents and targets. Med. Res. Rev. 22:531565.
18. De Clercq, E. 2005. New approach toward anti-HIV chemotherapy. J. Med. Chem. 48:12971313.
19. De Clercq, E.,, N. Yamamoto,, R. Pauwels,, M. Baba,, D. Schols,, H. Nakashima,, J. Balzarini,, Z. Debyser,, B. A. Murrer,, D. Schwartz,, D. Thornton,, G. Bridger,, S. Fricker,, G. Henson,, M. Abrams, and, D. Picker. 1992. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA 89:52865290.
20. De Clercq, E.,, N. Yamamoto,, R. Pauwels,, J. Balzarini,, M. Witvrouw,, K. De Vreese,, Z. Debyser,, B. Rosenwirth,, P. Peichl,, R. Datema,, D. Thornton,, R. Skerlj,, F. Gaul,, S. Radmanabhan,, G. Bridger,, G. Henson, and, M. Abrams. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicy-clam derivative JM3100. Antimicrob. Agents Chemother. 38:668674.
21. Donzella, G. A.,, D. Schols,, S. W. Lin,, J. A. Esté,, K. A. Nagashima,, P. J. Maddon,, G. P. Allaway,, T. P. Sakmar,, G. Henson,, E. De Clercq, and, J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:7277.
22. Doranz, B. J.,, K. Grovit-Ferbas,, M. P. Sharron,, S. H. Mao,, M. B. Goetz,, E. S. Daar,, R. W. Doms, and, W. A. O’Brien. 1997. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:13951400.
23. Dorr, P.,, M. Westby,, S. Dobbs,, P. Griffin,, B. Irvine,, M. Macartney,, J. Mori,, G. Rickett,, C. Smith-Burchnell,, C. Napier,, R. Webster,, D. Armour,, D. Price,, B. Stammen,, A. Wood, and, M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:47214732.
24. Dragic, T.,, A. Trkola,, D. A. Thompson,, E. G. Cormier,, F. A. Kajumo,, E. Maxwell,, S. W. Lin,, W. Ying,, S. O. Smith,, T. P. Sakmar, and, J. P. Moore. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA 97:56395644.
25. Esser, M. T.,, T. Mori,, I. Mondor,, Q. J. Sattentau,, B. Dey,, E. A. Berger,, M. R. Boyd, and, L. D. Lifson. 1999. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73:43604371.
26. Esté, J. A.,, D. Schols,, K. De Vreese,, K. Van Laethem,, A. M. Vandamme,, J. Desmyter, and, E. De Clercq. 1997. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:98104.
27. Fätkenheuer, G.,, A. L. Pozniak,, J. A. Johnson,, A. Plettenberg,, S. Staszewski,, A. I. Hoepelman,, M. S. Saag,, F. D. Goebel,, J. K. Rockstroh,, B. J. Dezube,, T. M. Jenkins,, C. Medhurst,, J. F. Sullivan,, C. Ridgway,, S. Abel,, I. T. James,, M. Youle, and, E. van der Ryst. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11:11701172.
28. Flexner, C.,, P. A. Barditch-Crovo,, D. M. Kornhauser,, H. Farzadegan,, L. J. Nerhood,, R. E. Chaisson,, K. M. Bell,, K. J. Lorentsen,, C. W. Hendrix,, B. G. Petty, and, P. S. Lietman. 1991. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother. 35:25442550.
29. Gulick, R.,, Z. Su,, C. Flexner,, M. Hughes,, P. Skolnik,, C. Godfrey,, T. Wilkin,, R. Gross,, A. Krambrink,, E. Coakley,, W. Greaves,, A. Zolopa,, M. Hirsch,, D. Kuritzkes, and ACTG 5211 Team. 2007. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results, abstr. TuAb102. Abstr. 4th IAS Conf. July 22–25, 2007. Sydney, Australia.
30. Gulick, R. M.,, Z. Su,, C. Flexner,, M. D. Hughes,, P. R. Skolnik,, T. J. Wilkin,, R. Gross,, A. Krambrink,, E. Coakley,, W. L. Greaves,, A. Zolopa,, R. Reichman,, C. Godfrey,, M. Hirsch,, D. R. Kuritzkes, and the AIDS Clinical Trials Group 5211 Team. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J. Infect. Dis. 196:304312.
31. Guo, Q.,, H. T. Ho,, I. Dicker,, L. Fan,, N. Zhou,, J. Friborg,, T. Wang,, B. V. McAuliffe,, H. G. Wang,, R. E. Rose,, H. Fang,, H. T. Scarnati,, D. R. Langley,, N. A. Meanwell,, R. Abraham,, R. J. Colonno, and, R. F. Lin. 2003. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77:1052810536.
32. Hamy, F.,, E. R. Felder,, G. Heizmann,, J. Lazdins,, F. Aboul-ela,, G. Varani,, J. Karn, and, T. Klimkait. 1997. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 94:35483553.
33. Hatse, S.,, K. Princen,, G. Bridger,, E. De Clercq, and, D. Schols. 2002. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527:255262.
34. Hendrix, C. W.,, A. C. Collier,, M. M. Lederman,, D. Schols,, R. B. Pollard,, S. Brown,, J. B. Jackson,, R. W. Coombs,, M. J. Glesby,, C. W. Flexner,, G. J. Bridger,, K. Badel,, R. T. MacFarland,, G. W. Henson,, G. Calandra, and the AMD3100 HIV Study Group. 2004. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37:12531262.
35. Hendrix, C. W.,, C. Flexner,, R. T. MacFarland,, C. Giandomenico,, E. J. Fuchs,, E. Redpath,, G. Bridger, and, G. W. Henson. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44:16671673.
36. Hirsch, M. S.,, F. Brun-Vézinet,, B. Clotet,, B. Conway,, D. R. Kuritzkes,, R. T. D’Aquila,, L. M. Demeter,, S. M. Hammer,, V. A. Johnson,, C. Loveday,, J. W. Mellors,, D. M. Jacobsen, and, D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37:113128.
37. Hu, Q.,, N. Mahmood, and, R. J. Shattock. 2007. High-mannosespecific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368:145154.
38. Ichiyama, K.,, S. Yokoyama-Kumakura,, Y. Tanaka,, R. Tanaka,, K. Hirose,, K. Bannai,, T. Edamatsu,, M. Yanaka,, Y. Niitani,, N. Miyano-Kurosaki,, H. Takaku,, Y. Koyanagi, and, N. Yamamoto. 2003. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 100:41854190.
39. Jiang, S.,, H. Lu,, S. Liu,, Q. Zhao,, Y. He, and, A. K. Debnath. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48:43494359.
40. Johnson, V. A.,, F. Brun-Vézinet,, B. Clotet,, H. F. Gunthard,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro, and, D. D. Richman. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119125.
41. Ketas, T. J.,, S. M. Schader,, J. Zurita,, E. Teo,, V. Polonis,, M. Lu,, P. J. Klasse, and, J. P. Moore. 2007. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 364:431440.
42. Kilby, J. M.,, S. Hopkins,, T. M. Venetta,, B. DiMassimo,, G A. Cloud,, J. Y. Lee,, L. Alldredge,, E. Hunter,, D. Lambert,, D. Bolognesi,, T. Matthews,, M. R. Johnson,, M. A. Nowak,, G. M. Shaw, and, M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:13021307.
43. Kilby, J. M.,, J. P. Lalezari,, J. J. Eron,, M. Carlson,, C. Cohen,, R. C. Arduino,, J. C. Goodgame,, J. E. Gallant,, P. Volberding,, R. L. Murphy,, F. Valentine,, M. S. Saag,, E. L. Nelson,, P. R. Sista, and, A. Dusek. 2002. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retrovir. 18:685693.
44. Koning, F. A.,, C. Koevoets,, T. J. K. van der Vorst, and, H. Schuite-maker. 2005. Sensitivity of primary R5 HIV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir. Ther. 10:231237.
45. Kuhmann, S. E.,, P. Pugach,, K. J. Kunstman,, J. Taylor,, R. L. Stan-field,, A. Snyder,, J. M. Strizki,, J. Riley,, B. M. Baroudy,, I. A. Wilson,, B. T. Korber,, S. M. Wolinsky, and, J. P. Moore. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78:27902807.
46. Kuritzkes, D. R.,, J. Jacobson,, W. G. Powderly,, E. Godofsky,, E. DeJesus,, F. Haas,, K. A. Reimann,, J. L. Larson,, P. O. Yarbough,, V. Curt, and, W. R. Shanahan, Jr. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189:286291.
47. Labrosse, B.,, A. Brelot,, N. Heveker,, N. Sol,, D. Schols,, E. De Clercq, and, M. Alizon. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicy-clam AMD3100. J. Virol. 72:63816388.
48. Lalezari, J.,, J. Goodrich,, E. DeJesus,, H. Lampiris,, R. Gulick,, M. Saag,, C. Ridgway,, M. McHale,, E. van der Ryst, and, H. Mayer. 2007. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada, abstr. 104bLB. 14th Conf. Retrovir. Opportun. Infect. February 25–28, 2007. Los Angeles, CA.
49. Lalezari, J.,, M. Thompson,, P. Kumar,, P. Piliero,, R. Davey,, K. Patterson,, A. Shachoy-Clark,, K. Adkison,, J. Demarest,, Y. Lou,, M. Berrey, and, S. Piscitelli. 2005. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19:14431448.
50. Lalezari, J. P.,, K. Henry,, M. O’Hearn,, J. S. Montaner,, P. J. Piliero,, B. Trottier,, S. Walmsley,, C. Cohen,, D. R. Kuritzkes,, J. J. Eron, Jr.,, J. Chung,, R. DeMasi,, L. Donatacci,, C. Drobnes,, J. Delehanty,, M Salgo, and the TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:21752185.
51. Lazzarin, A.,, B. Clotet,, D. Cooper,, J. Reynes,, K. Arasteh,, M. Nelson,, C. Katlama,, H. J. Stellbrink,, J. F. Delfraissy,, J. Lange,, L. Huson,, R. DeMasi,, C. Wat,, J. Delehanty,, C. Drobnes,, M. Salgo, and the TORO 2 Study Group. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:21862195.
52. Lee, L. M.,, J. M. Karon,, R. Selik,, J. J. Neal, and, P. L. Fleming. 2001. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 285:13081315.
53. Li, S.,, J. Juarez,, M. Alali,, D. Dwyer,, R. Collman,, A. Cunningham, and, H. M. Naif. 1999. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J. Virol. 73:97419755.
54. Lin, P. F.,, W. Blair,, T. Wang,, T. Spicer,, Q. Guo,, N. Zhou,, Y. F. Gong,, H. G. Wang,, R. Rose,, G. Yamanaka,, B. Robinson,, C. B. Li,, R. Fridell,, C. Deminie,, G. Demers,, Z. Yang,, L. Zadjura,, N. Mean-well, and, R. Colonno. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100:1101311008.
55. Liu, R.,, W. A. Paxton,, S. Choe,, D. Ceradini,, S. R. Martin,, R. Horuk,, M. E. MacDonald,, H. Stuhlmann,, R. A. Koup, and, N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367377.
56. Lu, J.,, P. Sista,, F. Giguel,, M. Greenberg, and, D. R. Kuritzkes. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78:46284637.
57. Lu, M.,, S. C. Blacklow, and, P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:10751082.
58. Maeda, K.,, D. Das,, H. Ogata-Aoki,, H. Nakata,, T. Miyakawa,, Y. Tojo,, R. Norman,, Y. Takaoka,, J. Ding,, G. F. Arnold,, E. Arnold, and, H. Mitsuya. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281:1268812698.
59. Maeda, K.,, H. Nakata,, Y. Koh,, T. Miyakawa,, H. Ogata,, Y. Takaoka,, S. Shibayama,, K. Sagawa,, D. Fukushima,, J. Moravek,, Y. Koyanagi, and, H. Mitsuya. 2004. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78:86548662.
60. Marozsan, A. J.,, S. E. Kuhmann,, T. Morgan,, C. Herrera,, E. Rivera-Troche,, S. Xu,, B. M. Baroudy,, J. Strizki, and, J. P. Moore. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:182199.
61. Melby, T.,, P. Sista,, R. DeMasi,, T. Kirkland,, N. Roberts,, M. Salgo,, G. Heilek-Snyder,, N. Cammack,, T. J. Matthews, and, M. L. Greenberg. 2006. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res. Hum. Retrovir. 22:375385.
62. Meylan, P. R.,, R. S. Kornbluth,, I. Zbinden, and, D. D. Richman. 1994. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. Antimicrob. Agents Chemother. 38:29102916.
63. Mitsuya, H.,, D. J. Looney,, S. Kuno,, R. Ueno,, F. Wong-Staal, and, S. Broder. 1988. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240:646649.
64. Mori, J.,, M. Mosley,, M. Lewis,, P. Simpson,, J. Toma,, W. Huang,, J. Whitcomb,, G. Ciaramella, and, M. Westby. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2s, abstr. 10. 16th Int. HIV Drug Resist. Workshop. June 12–16, 2007. Barbados, West Indies.
65. Moulard, M.,, H. Lortat-Jacob,, I. Mondor,, G. Roca,, R. Wyatt,, J. Sodroski,, L. Zhao,, W. Olson,, P. D. Kwong, and, Q. J. Sattentau. 2000. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:19481960.
66. Murakami, T.,, T. Nakajima,, Y. Koyanagi,, K. Tachibana,, N. Fujii,, H. Tamamura,, N. Yoshida,, M. Waki,, A. Matsumoto,, O. Yoshie,, T. Kishimoto,, N. Yamamoto, and, T. Nagasawa. 1997. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:13891393.
67. Myszka, D. G.,, R. W. Sweet,, P. Hensley,, M. Brigham-Burke,, P. D. Kwong,, W. A. Hendrickson,, R. Wyatt,, J. Sodroski, and, M. L. Doyle. 2000. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. USA 97:90269031.
68. Nagasawa, T.,, S. Hirota,, K. Tachibana,, N. Takakura,, S. Nishikawa,, Y. Kitamura,, N. Yoshida,, H. Kikutani, and, T. Kishimoto. 1996. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:635638.
69. Nakata, H.,, K. Maeda,, T. Miyakawa,, S. Shibayama,, M. Matsuo,, Y. Takaoka,, M. Ito,, Y. Koyanagi, and, H. Mitsuya. 2005. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor γ-chain-knocked-out AIDS mouse model. J. Virol. 79:20872096.
70. Nelson, M.,, K. Arasteh,, B. Clotet,, D. A. Cooper,, K. Henry,, C. Katlama,, J. P. Lalezari,, A. Lazzarin,, J. S. Montaner,, M. O’Hearn,, P. J. Piliero,, J. Reynes,, B. Trottier,, S. L. Walmsley,, C. Cohen,, J. J. Eron, Jr.,, D. R. Kuritzkes,, J. Lange,, H. J. Stellbrink,, J. F. Delfraissy,, N. E. Buss,, L. Donatacci,, C. Wat,, L. Smiley,, M. Wilkinson,, A. Valentine,, D. Guimaraes,, R. Demasi,, J. Chung, and, M. P. Salgo. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 clinical trials. J. Acquir. Immune Defic. Syndr. 40:404412.
71. Nelson, M.,, G. Fätkenheuer,, I. Konourina,, A. Lazzarin,, N. Clumeck,, A. Horban,, M. Tawadrous,, J. Sullivan,, H. Mayer, and, E. van der Ryst. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results, abstr. 104aLB. 14th Conf. Retrovir. Opportun. Infect. February 25–28, 2007. Los Angeles, CA.
72. Nishikawa, M.,, K. Takashima,, T. Nishi,, R. A. Furuta,, N. Kanzaki,, Y. Yamamoto, and, J. Fujisawa. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother. 49:47084715.
73. Penn, M. L.,, J. C. Grivel,, B. Schramm,, M. A. Goldsmith, and, L. Margolis. 1999. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc. Natl. Acad. Sci. USA 96:663668.
74. Princen, K.,, S. Hatse,, K. Vermeire,, S. Aquaro,, E. De Clercq,, L. O. Gerlach,, M. Rosenkilde,, T. W. Schwartz,, R. Skerlj,, G. Bridger, and, D. Schols. 2004. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. 78:1299613006.
75. Rimsky, L. T.,, D. C. Shugars, and, T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986993.
76. Saag, M. S.,, J. M. Jacobson,, M. Thompson,, M. Fischl,, R. Liporace,, R. C. Reichman,, R. R. Redfield,, C. J. Fichtenbaum,, B. S. Zingman,, M. C. Patel,, P. D’Ambrosio,, M. Michael,, H. Kroger,, H. Ly,, Y. Rotshteyn,, J. J. Stavola,, P. J. Maddon,, A. B. Kremer, and, W. C. Olson. Antiviral effects and tolerability of the CCR5 monoclonal antibody PRO 140: a proof of concept study in HIV-infected individuals, abstr. WESS201. 4th Int. AIDS Soc. Conf. HIV Pathog., Treatment, Prevention. July 22–25, 2007. Sydney, Australia.
77. Samson, M.,, F. Libert,, B. J. Doranz,, J. Rucker,, C. Liesnard,, C. M. Farber,, S. Saragosti,, C. Lapoumeroulie,, J. Cognaux,, C. Forceille,, G. Muyldermans,, C. Verhofstede,, G. Burtonboy,, M. Georges,, T. Imai,, S. Rana,, Y. Yi,, R. J. Smyth,, R. G. Collman,, R. W. Doms,, G. Vassart, and, M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722725.
78. Schols, D.,, J. A. Esté,, C. Cabrera, and, E. De Clercq. 1998. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72:40324037.
79. Schols, D.,, S. Struyf,, J. Van Damme,, J. A. Esté,, G. Henson, and, E. De Clercq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:13831388.
80. Schurmann, D.,, G. Fätkenheuer,, J. Reynes,, C. Michelet,, F. Raffi,, J. van Lier,, M. Caceres,, A. Keung,, A. Sansone-Parsons,, L. M. Dunkle, and, C. Hoffmann. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:12931299.
81. Si, Z.,, N. Madani,, J. M. Cox,, J. J. Chruma,, J. C. Klein,, A. Schon,, N. Phan,, L. Wang,, A. C. Biorn,, S. Cocklin,, I. Chaiken,, E. Freire,, A. B. Smith III, and, J. G. Sodroski. 2004. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. USA 101:50365041.
82. Sista, P. R.,, T. Melby,, D. Davison,, L. Jin,, S. Mosier,, M. Mink,, E. L. Nelson,, R. DeMasi,, N. Cammack,, M. P. Salgo,, T. J. Matthews, and, M. L. Greenberg. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:17871794.
83. Strizki, J. M.,, C. Tremblay,, S. Xu,, L. Wojcik,, N. Wagner,, W. Gonsiorek,, R. W. Hipkin,, C. C. Chou,, C. Pugliese-Sivo,, Y. Xiao,, J. R. Tagat,, K. Cox,, T. Priestley,, S. Sorota,, W. Huang,, M. Hirsch,, G. R. Reyes, and, B. M. Baroudy. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49:49114919.
84. Strizki, J. M.,, S. Xu,, N. E. Wagner,, L. Wojcik,, J. Liu,, Y. Hou,, M. Endres,, A. Palani,, S. Shapiro,, J. W. Clader,, W. J. Greenlee,, J. R. Tagat,, S. McCombie,, K. Cox,, A. B. Fawzi,, C. C. Chou,, C. Pugliese-Sivo,, L. Davies,, M. E. Moreno,, D. D. Ho,, A. Trkola,, C. A. Stoddart,, J. P. Moore,, G. R. Reyes, and, B. M. Baroudy. 2001. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:1271812723.
85. Sumner-Smith, M.,, Y. Zheng,, Y. P. Zhang,, E. M. Twist, and, S. C. Climie. 1995. Antiherpetic activities of N-α-acetyl-nona-d-arginine amide acetate. Drugs Exp. Clin. Res. 21:16.
86. Tachibana, K.,, S. Hirota,, H. Iizasa,, H. Yoshida,, K. Kawabata,, Y. Kataoka,, Y. Kitamura,, K. Matsushima,, N. Yoshida,, S. Nishikawa,, T. Kishimoto, and, T. Nagasawa. 1998. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:591594.
87. Takashima, K.,, H. Miyake,, N. Kanzaki,, Y. Tagawa,, X. Wang,, Y. Sugihara,, Y. Iizawa, and, M. Baba. 2005. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob. Agents Chemother. 49:34743482.
88. Tremblay, C. L.,, F. Giguel,, T. C. Chou,, H. Dong,, K. Takashima, and, M. S. Hirsch. 2005. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro. Antivir. Ther. 10:967968.
89. Tremblay, C. L.,, F. Giguel,, Y. Guan,, T. C. Chou,, K. Takashima, and, M. S. Hirsch. 2005. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob. Agents Chemother. 49:34833485.
90. Trkola, A.,, T. J. Ketas,, K. A. Nagashima,, L. Zhao,, T. Cilliers,, L. Morris,, J. P. Moore,, P. J. Maddon, and, W. C. Olson. 2001. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75:579588.
91. Trkola, A.,, S. E. Kuhmann,, J. M. Strizki,, E. Maxwell,, T. Ketas,, T. Morgan,, P. Pugach,, S. Xu,, L. Wojcik,, J. Tagat,, A. Palani,, S. Shapiro,, J. W. Clader,, S. McCombie,, G. R. Reyes,, B. M. Baroudy, and, J. P. Moore. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99:395400.
92. Trottier, B.,, S. Walmsley,, J. Reynes,, P. Piliero,, M. O’Hearn,, M. Nelson,, J. Montaner,, A. Lazzarin,, J. Lalezari,, C. Katlama,, K. Henry,, D. Cooper,, B. Clotet,, K. Arasteh,, J. F. Delfraissy,, H. J. Stellbrink,, J. Lange,, D. Kuritzkes,, J. J. Eron, Jr.,, C. Cohen,, T. Kinchelow,, A. Bertasso,, E. Labriola-Tompkins,, A. Shikhman,, B. Atkins,, L. Bourdeau,, C. Natale,, F. Hughes,, J. Chung,, D. Guimaraes,, C. Drobnes,, S. Bader-Weder,, R. Demasi,, L. Smiley, and, M. P. Salgo. 2005. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J. Acquir. Immune Defic. Syndr. 40:413421.
93. Tsai, C. C.,, P. Emau,, Y. Jiang,, M. B. Agy,, R. J. Shattock,, A. Schmidt,, W. R. Morton,, K. R. Gustafson, and, M. R. Boyd. 2004. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retrovir. 20:1118.
94. Tsibris, A. M. N.,, R. M. Gulick,, Z. Su,, M. D. Hughes,, C. Flexner,, T. Wilkin,, R. Gross,, M. Hirsch,, P. R. Skolnik,, E. Coakley,, W. L. Greaves, and, D. R. Kuritzkes. 2007. In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: findings from ACTG 5211, abstr. 13. 16th Int. HIV Drug Resist. Workshop. June 12–16, 2007. Barbados, West Indies.
95. Tuttle, D. L.,, C. B. Anders,, M. J. Aquino-De Jesus,, P. P. Poole,, S. L. Lamers,, D. R. Briggs,, S. M. Pomeroy,, L. Alexander,, K. W. Peden,, W. A. Andiman,, J. W. Sleasman, and, M. M. Goode-now. 2002. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res. Hum. Retrovir. 18:353362.
96. Veazey, R. S.,, P. J. Klasse,, T. J. Ketas,, J. D. Reeves,, M. Piatak, Jr.,, K. Kunstman,, S. E. Kuhmann,, P. A. Marx,, J. D. Lifson,, J. Dufour,, M. Mefford,, I. Pandrea,, S. M. Wolinsky,, R. W. Doms,, J. A. DeMartino,, S. J. Siciliano,, K. Lyons,, M. S. Springer, and, J. P. Moore. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198:15511562.
97. Veazey, R. S.,, P. J. Klasse,, S. M. Schader,, Q. Hu,, T. J. Ketas,, M. Lu,, P. A. Marx,, J. Dufour,, R. J. Colonno,, R. J. Shattock,, M. S. Springer, and, J. P. Moore. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99102.
98. Veazey, R. S.,, M. S. Springer,, P. A. Marx,, J. Dufour,, P. J. Klasse, and, J. P. Moore. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 11:12931294.
99. Walker, D. K.,, S. Abel,, P. Comby,, G. J. Muirhead,, A. N. Nedderman, and, D. A. Smith. 2005. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33:587595.
100. Watson, C.,, S. Jenkinson,, W. Kazmierski, and, T. Kenakin. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67:12681282.
101. Wei, X.,, J. M. Decker,, H. Liu,, Z. Zhang,, R. B. Arani,, J. M. Kilby,, M. S. Saag,, X. Wu,, G. M. Shaw, and, J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:18961905.
102. Weissenhorn, W.,, A. Dessen,, S. C. Harrison,, J. J. Skehel, and, D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426430.
103. Westby, M.,, C. Smith-Burchnell,, J. Mori,, M. Lewis,, M. Mosley,, M. Stockdale,, P. Dorr,, G. Ciaramella, and, M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:23592371.
104. Wild, C. T.,, D. C. Shugars,, T. K. Greenwell,, C. B. McDanal, and, T. J. Matthews. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:97709774.
105. Witvrouw, M., and, E. De Clercq. 1997. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen. Pharmacol. 29:497511.
106. Witvrouw, M.,, V. Fikkert,, A. Hantson,, C. Pannecouque,, B. R. O’Keefe,, J. McMahon,, L. Stamatatos,, E. De Clercq, and, A. Bolmstedt. 2005. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol. 79:77777784.
107. Wu, L.,, N. P. Gerard,, R. Wyatt,, H. Choe,, C. Parolin,, N. Ruffing,, A. Borsetti,, A. A. Cardoso,, E. Desjardin,, W. Newman,, C. Gerard, and, J. Sodroski. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179183.
108. Yang, Z.,, L. Zadjura,, C. D’Arienzo,, A. Marino,, K. Santone,, L. Klunk,, D. Greene,, P. F. Lin,, R. Colonno,, T. Wang,, N. Meanwell, and, S. Hansel. 2005. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. Biopharm. Drug Dispos. 26:387402.
109. Yeni, P. G.,, S. M. Hammer,, C. C. Carpenter,, D. A. Cooper,, M. A. Fischl,, J. M. Gatell,, B. G. Gazzard,, M. S. Hirsch,, D. M. Jacobsen,, D. A. Katzenstein,, J. S. Montaner,, D. D. Richman,, M. S. Saag,, M. Schechter,, R. T. Schooley,, M. A. Thompson,, S. Vella, and, P. A. Volberding. 2002. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222235.
110. Zhang, X. Q.,, M. Sorensen,, M. Fung, and, R. T. Schooley. 2006. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob. Agents Chemother. 50:22312233.

Tables

Generic image for table
Table 1.

Entry inhibitors approved for clinical use or in clinical studies

Citation: Baba M. 2009. Entry Inhibitors of Human Immunodeficiency Virus, p 19-32. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch2

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error